hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06333171, orgStudyIdInfo id: 00003872, briefTitle: 4-aminopyridine for Skin Wound Healing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2027-09, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: John Elfar, class: OTHER, descriptionModule briefSummary: Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing., conditionsModule conditions: Wounds, conditions: Wound of Skin, conditions: Wound Heal, conditions: Wounds and Injuries, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a double-blind, randomized, placebo-controlled trial design., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Subjects in both aims will be assigned to Group A or Group B using a randomization scheme. Each study participant for each aim is randomly assigned to either treatment of placebo using permuted block randomization, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: 4-Aminopyridine, interventions name: Placebo, outcomesModule primaryOutcomes measure: Return of skin integrity and wound closure after skin punch biopsy, secondaryOutcomes measure: The effect of 4-AP on the hair number and growth at the skin punch biopsy site., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Arizona, city: Tucson, state: Arizona, zip: 85724, country: United States, contacts name: Andrea Horne, role: CONTACT, phone: 520-626-6456, email: ahh@arizona.edu, geoPoint lat: 32.22174, lon: -110.92648, hasResults: False
protocolSection identificationModule nctId: NCT06333145, orgStudyIdInfo id: EDRA, briefTitle: ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-04, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Tongji Hospital, class: OTHER, descriptionModule briefSummary: Exploring the ED90 of remimazolam in Drug-induced Sleep Endoscopy in adults at different BMI groups., conditionsModule conditions: Effect of Drug, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Remimazolam, outcomesModule primaryOutcomes measure: Ramsey Sedation Scale, secondaryOutcomes measure: Time records, secondaryOutcomes measure: Use of drugs, secondaryOutcomes measure: Respiratory suppression incidence, secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, secondaryOutcomes measure: Incidence of PACU Adverse Reactions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital, status: RECRUITING, city: Wuhan, state: Hubei, zip: 430000, country: China, contacts name: aijun xu, Dr., role: CONTACT, phone: 027-83663173, email: ajxu@tjh.tjmu.edu.cn, contacts name: yuan Bi, Dr., role: CONTACT, phone: 027-18972718216, email: 18972718216@163.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06333132, orgStudyIdInfo id: DiabEAT.it, briefTitle: Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat), acronym: DiabEATit, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2026-02-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Azienda Ospedaliero, Universitaria Pisana, class: OTHER, descriptionModule briefSummary: The goal of this mechanistic study is to investigate the role of incretin hormones on weight loss-induced type 2 diabetes remission., conditionsModule conditions: Obesity, conditions: Diabetes Mellitus Type 2 in Obese, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Weight loss-induced Diabetes Remission, outcomesModule primaryOutcomes measure: Number of participants with incretin effect's restoration after achieving weightloss-induced diabetes remission, secondaryOutcomes measure: Rate of sustained weightloss-induced diabetes remission assessed by 2 consecutive HbA1c <48mmol/mol within 6 months, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azienda Ospedaliero-Universitaria Pisana, city: Pisa, state: PI, zip: 56127, country: Italy, geoPoint lat: 43.70853, lon: 10.4036, hasResults: False
protocolSection identificationModule nctId: NCT06333119, orgStudyIdInfo id: 72867572-050.01.04-320, briefTitle: The Relationship Between Urinary Incontinence and Motor Symptoms, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-01-31, completionDateStruct date: 2024-02-15, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Pinar Yasar, class: OTHER, descriptionModule briefSummary: There is no study in the literature examining the relationship between urinary incontinence and motor symptoms in individuals with stroke. The aim of this study is to determine the relationship between urinary incontinence and spasticity, balance and walking, which negatively affect quality of life and functional performance after stroke., conditionsModule conditions: Stroke, conditions: Urinary Incontinence, conditions: Motor Skills Disorders, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 46, type: ACTUAL, armsInterventionsModule interventions name: modified rankin scale, outcomesModule primaryOutcomes measure: relationship with between urinary incontinence and motor symptoms, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Suleyman Demirel University, city: Isparta, country: Turkey, geoPoint lat: 37.76444, lon: 30.55222, hasResults: False
protocolSection identificationModule nctId: NCT06333106, orgStudyIdInfo id: FICUS - 2024/16FEV/077, briefTitle: PoCUS Diagnostic Accuracy for Fecal Impaction in the Emergency Department: A Prospective Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Cliniques universitaires Saint-Luc- Université Catholique de Louvain, class: OTHER, collaborators name: Université de Liège, collaborators name: Grand Hôpital de Charleroi, collaborators name: Clinique Saint-Jean, Bruxelles, collaborators name: Clinique Saint Pierre Ottignies, descriptionModule briefSummary: Many medical and paramedical specialties regularly use point-of-care ultrasound (PoCUS) in clinical practice. The diagnosis of fecal impaction is quite common in the elderly living in nursing homes with a prevalence of 47.3%. Fecal impaction remains a major source of morbidity, while its etiology is often multifactorial and its diagnosis challenging. Current recommendations for the diagnosis of fecal impaction support the use of plain abdominal x-rays. PoCUS is a non-irradiating procedure and a clinical diagnostic tool that can be used in a variety of ways during abdominal examinations. Most scientific societies encourage the use of PoCUS to respond to a specific clinical question rather than to provide a diagnosis, which is usually confirmed by conventional ultrasound. However, the combination of physical examination and PoCUS may improve the diagnostic approach. This multicentric prospective study protocol aims to evaluate the diagnostic accuracy of PoCUS in patients aged 75 years or older with suspected fecal impaction in the emergency department compared with plain abdominal x-ray (or abdominal CT scan if required as part of the emergency department investigations)., conditionsModule conditions: Fecal Impaction of Colon, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 247, type: ESTIMATED, armsInterventionsModule interventions name: POCUS diagnostic value, outcomesModule primaryOutcomes measure: Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room, secondaryOutcomes measure: Influence of BMI on the diagnosis of fecal impaction at PoCUS, secondaryOutcomes measure: Influence of bladder repletion on the diagnosis of fecal impaction using PoCUS, secondaryOutcomes measure: Influence of patient echogenicity on the diagnosis of fecal impaction using PoCUS, eligibilityModule sex: ALL, minimumAge: 75 Years, maximumAge: 130 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06333093, orgStudyIdInfo id: NL82178.018.22, briefTitle: Duodenal tIssue ResEction aCquisiTion (DIRECT) Study, acronym: DIRECT, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-10, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), class: OTHER, descriptionModule briefSummary: To evaluate the quality of cold snare resection specimens of duodenal mucosa tissue in patients undergoing an upper gastrointestinal interventional endoscopy in order to improve the processing of histological samples and its assessment in general and for future duodenal ablation studies., conditionsModule conditions: Duodenum Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cold snare, outcomesModule primaryOutcomes measure: Acquiring larger pieces of tissue from the duodenum, primaryOutcomes measure: Histopatholocial assessment of larger pieces of tissue from the duodenum, primaryOutcomes measure: Checking if the tissue is of good quality enough for single cell RNA sequencing, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Amsterdam UMC, status: RECRUITING, city: Amsterdam, state: North-Holland, zip: 1105 AZ, country: Netherlands, contacts name: Celine BE Busch, MD, role: CONTACT, phone: +31621357593, email: diabetes-onderzoek@amsterdamumc.nl, contacts name: Jacques JG Bergman, MD PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Celine BE Busch, MD, role: SUB_INVESTIGATOR, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False
protocolSection identificationModule nctId: NCT06333080, orgStudyIdInfo id: N-20220017, briefTitle: The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin, acronym: DIACRON, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Aalborg University Hospital, class: OTHER, descriptionModule briefSummary: The objective of the trial is to investigate the effect of adherence to oral semaglutide dosing instructions on glycaemic control in people with type 2 diabetes, which are dysregulated on metformin and naïve to second line antidiabetic treatment., conditionsModule conditions: Diabetes Mellitus, Type 2, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Time-in-Range (TIR), secondaryOutcomes measure: Pre-dose Fasting, secondaryOutcomes measure: Post-dose Fasting, secondaryOutcomes measure: Occurrence of nausea or vomiting, secondaryOutcomes measure: Water Intake at Dosing Time, secondaryOutcomes measure: Treatment-Related Impact Measure for Diabetes (TRIM-D), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Steno Diabetes Center North Denmark, status: RECRUITING, city: Aalborg, zip: 9000, country: Denmark, contacts name: Mette Pilegaard Rasmussen, BSc, role: CONTACT, phone: 00 45 30 36 46 84, email: mpr@rn.dk, contacts name: Peter Vestergaard, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Nynne S Holdt-Caspersen, MSc, role: SUB_INVESTIGATOR, geoPoint lat: 57.048, lon: 9.9187, hasResults: False
protocolSection identificationModule nctId: NCT06333067, orgStudyIdInfo id: Sofwave21, briefTitle: Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-11, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-11-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Sofwave Medical LTD, class: INDUSTRY, descriptionModule briefSummary: Open-label, non-randomized single-arm prospective, multi-center, self-controlled clinical study with masked evaluation., conditionsModule conditions: Lax Skin, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Sofwave, outcomesModule primaryOutcomes measure: Primary Outcome Measure, eligibilityModule sex: ALL, minimumAge: 35 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Costal Skin & Eye Institute, status: RECRUITING, city: La Mesa, state: California, zip: 91942, country: United States, contacts name: Christopher V.Crosby, MD, role: CONTACT, email: research@coastalskineye.com, contacts name: Christopher V.Crosby, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.76783, lon: -117.02308, locations facility: Skin Wellness Dermatology Associates, status: RECRUITING, city: Durham, state: North Carolina, zip: 27713, country: United States, contacts name: Talasia Smith, role: CONTACT, phone: 919-294-9440, email: cst@skinwellnessdermatology.com, contacts name: Brooke Jackson, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.99403, lon: -78.89862, hasResults: False
protocolSection identificationModule nctId: NCT06333054, orgStudyIdInfo id: NCLIN0091/ 14ct/mp37li, briefTitle: Safety and Efficacy of a Head Lice Shampoo, statusModule overallStatus: COMPLETED, startDateStruct date: 2014-10-13, primaryCompletionDateStruct date: 2015-06-08, completionDateStruct date: 2015-06-08, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Oystershell NV, class: INDUSTRY, descriptionModule briefSummary: This study is designed to compare the effectiveness and safety of test head lice shampoo (Test product) versus Goldgeist® Forte (reference product) following two applications., conditionsModule conditions: Head Lice, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 109, type: ACTUAL, armsInterventionsModule interventions name: Pyrethrum Extract, interventions name: Silcap Shampoo, outcomesModule primaryOutcomes measure: Cure Rate superior to 70% for the test product, secondaryOutcomes measure: Cure Rate superior to 70% for the reference product, secondaryOutcomes measure: Superior cure rate to the reference, secondaryOutcomes measure: Non-inferiority rate to the reference, secondaryOutcomes measure: Local tolerability, secondaryOutcomes measure: Global tolerability, secondaryOutcomes measure: Skin irritation assessment, secondaryOutcomes measure: Eye irritation assessment, secondaryOutcomes measure: Esthetical effect of the anti-lice products, secondaryOutcomes measure: Adverse Events (AEs), otherOutcomes measure: Severity of the lice infestation, eligibilityModule sex: ALL, minimumAge: 1 Year, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CardioSec Clinical Research GmbH, city: Erfurt, zip: 99084, country: Germany, geoPoint lat: 50.9787, lon: 11.03283, hasResults: False
protocolSection identificationModule nctId: NCT06333041, orgStudyIdInfo id: 32977-01-00, briefTitle: Study of Cannabidiol in Sanfilippo Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2027-05, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test cannabidiol in Sanfilippo syndrome. The main questions it aims to answer are: 1) determine the safety of cannabidiol in Sanfilippo syndrome, and 2) explore the efficacy of cannabidiol in treating the neurobehavioral symptoms and functional outcomes of Sanfilippo syndrome.Each participant's caregiver will be asked to complete surveys related to the participant's behavior, mood, sleep, stooling, pain, and caregiver stress intermittently throughout the study. All participants will be enrolled into one of two cohorts based on enrollment order:1. Sentinel Safety Cohort (first 5 participants) - all participants treated with Epidiolex (cannabidiol)2. Controlled Cohort (next 30 participants) - participants randomized 1:1 (equal chance) to start treatment with Epidiolex (cannabidiol) or placebo for 16 weeks, followed by an 8-week washout period (no treatment). Participants then switch to the opposite treatment group for 16 weeks followed by all participants treated for 52 weeks with Epidiolex (cannabidiol)., conditionsModule conditions: Sanfilippo Syndrome, conditions: Mucopolysaccharidosis III, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Double-blind, placebo-controlled, cross-over study, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Epidiolex, interventions name: Placebo, outcomesModule primaryOutcomes measure: Sanfilippo Behavior Rating Scale (SBRS)- mood/anger/aggression score, eligibilityModule sex: ALL, minimumAge: 4 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, city: Torrance, state: California, zip: 90502, country: United States, contacts name: Cristi Williams, role: CONTACT, email: cristi.williams@lundquist.org, contacts name: Lynda Polgreen, MD, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.83585, lon: -118.34063, hasResults: False
protocolSection identificationModule nctId: NCT06333028, orgStudyIdInfo id: 938, briefTitle: A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Bausch & Lomb Incorporated, class: INDUSTRY, descriptionModule briefSummary: A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing Cataract Extraction, conditionsModule conditions: Cataract, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: enVista Aspire EA IOLs, outcomesModule primaryOutcomes measure: Mean binocular BCDVA (logMAR) at Visit 1, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SITE 104, city: Dover, state: New Jersey, zip: 07801, country: United States, geoPoint lat: 40.88399, lon: -74.5621, locations facility: Site 105, city: Woodland Park, state: New Jersey, zip: 07424, country: United States, geoPoint lat: 40.88982, lon: -74.19487, locations facility: Site 103, city: Garden City, state: New York, zip: 11530, country: United States, geoPoint lat: 40.72677, lon: -73.6343, locations facility: Site 106, city: Charleston, state: South Carolina, zip: 29407, country: United States, geoPoint lat: 32.77657, lon: -79.93092, locations facility: Site 101, city: Sugar Land, state: Texas, zip: 77478, country: United States, geoPoint lat: 29.61968, lon: -95.63495, locations facility: Site 102, city: Mount Pleasant, state: Wisconsin, zip: 53405, country: United States, geoPoint lat: 42.69743, lon: -87.85577, hasResults: False